A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...
The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for ...
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...
The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, ...
The US Food and Drug Administration (FDA) has early this week approved GSK's new antibiotic, Blujepa (gepotidacin), for the ...
"The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women," said GSK's chief scientific offer Tony Wood, pointing out that around 16 million women in the ...
The drug, known in development as gepotidacin, will be marketed under the brand name Blujepa. GSK said it plans to launch the new product in the second half of this year. Uncomplicated UTIs are ...
The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...
The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...
The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for treating uncomplicated urinary tract infections (uUTIs) in adult females ...
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...